American Renal Associates (ARA) is Downgraded by Goldman to Sell

American Renal Associates (ARA) was Downgraded by Goldman to ” Sell”. Earlier the firm had a rating of “Neutral ” on the company shares. Goldman advised their investors in a research report released on Nov 21, 2016.

Many Wall Street Analysts have commented on American Renal Associates. American Renal Associates was Downgraded by Goldman to ” Sell” on Nov 21, 2016.

On the company’s financial health, American Renal Associates reported $0.28 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Nov 10, 2016. Analyst had a consensus of $0.24. The company had revenue of $192.96 million for the quarter, compared to analysts expectations of $189.87 million. The company’s revenue was up 14.9% compared to the same quarter last year.

In a different news, on Apr 27, 2016, Syed T Kamal (PRESIDENT) purchased 500 shares at $22.00 per share price. According to the SEC, on Apr 27, 2016, Michael Ray Costa (VP, GC AND SECRETARY) purchased 370 shares at $22.00 per share price. On Apr 27, 2016, Joseph A Carlucci (CEO) purchased 500 shares at $22.00 per share price, according to the Form-4 filing with the securities and exchange commission.

American Renal Associates

Leave a Reply

American Renal Associates - Is it time to Sell?

Top Brokerage Firms are advising their investors on American Renal Associates. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.